Bayer (BAYN) Corporate presentation summary

Strategic positioning and market overview

• Operates as a global leader in health and nutrition, with strong positions in crop science, pharmaceuticals, and consumer health, addressing fundamental human needs and major societal challenges.

• Focuses on innovation, investing ~€6bn annually in R&D, and leveraging digital solutions and iconic brands across divisions.

• Responds to global megatrends such as population growth, aging, and ecosystem pressures, with a mission to deliver health for all and hunger for none.

Financial performance and outlook

• Net sales for 2025 reached €45.6bn, with a core EPS of €4.91 and free cash flow of €2.1bn; litigation payouts significantly impacted cash flow.

• 2026 outlook projects net sales of €45.0–47.0bn, EBITDA before special items of €9.6–10.1bn, and net financial debt rising to €32–33bn, reflecting ongoing litigation costs.

• Organizational savings of €2bn targeted by end of 2026 through a new operating model focused on efficiency and customer centricity.

Strategic priorities and transformation

• Prioritizes pharma growth and pipeline revitalization, litigation containment, cash generation, crop science profitability, and a new operating model.

• Dynamic Shared Ownership model aims to flatten the organization, accelerate innovation, and improve resource allocation.

• Capital allocation emphasizes debt reduction, focused R&D, and limited acquisitions to improve financial flexibility.